Native Immune Cells
Cells isolated and administered without genetic modification, although they may be selected, activated or expanded outside the body.
CELLMEX Scientific Library
Immune-Cell Therapies
Immune-cell therapies use living cells of the immune system to recognise, regulate or eliminate defined biological targets. These platforms include unmodified, activated, expanded, antigen-directed and genetically engineered immune-cell products.
Scientific Definition
What exactly is an immune-cell therapy?
Immune-cell therapy is a form of cellular medicine in which leukocytes are collected, selected, activated, expanded, differentiated, genetically modified or otherwise prepared for a defined therapeutic purpose.
The cells may come from the patient autologously, from a compatible donor allogeneically, from a qualified cell bank, or from a haematopoietic progenitor-cell source.
Unlike a conventional pharmaceutical molecule, an immune-cell product is biologically active, heterogeneous and capable of responding to signals within the patient after administration.
Antigen-Directed Cells
Cells selected, trained, loaded or expanded to recognise a defined tumour, pathogen or antigen.
Engineered Immune Cells
Cells genetically modified to express a receptor, signalling system or other therapeutic characteristic.
Immune-Cell Biology
Recognition, activation and biological response
Immune-cell therapies use mechanisms already present within innate or adaptive immunity and redirect, reinforce or regulate those mechanisms for a defined medical objective.
Target Recognition
Immune cells recognise antigens, altered proteins, stress signals or changes in major histocompatibility-complex expression.
Cellular Activation
Receptor engagement and co-stimulatory signals may activate proliferation, cytokine production, cytotoxicity or antigen presentation.
Cytotoxic Activity
Activated T cells and NK cells may release perforin, granzymes or death-receptor signals that contribute to target-cell elimination.
Antigen Presentation
Dendritic cells process antigens and present selected antigen fragments to T cells, helping initiate or direct adaptive immune responses.
Immune Regulation
Regulatory T cells and other suppressive immune populations may limit excessive inflammation, autoimmunity or unwanted immune activation.
Immune Memory
Certain activated T-cell populations may persist and contribute to longer-term immunological surveillance.
Principal Cellular Platforms
Major categories of immune-cell therapy
Each platform is defined by its source cell, biological mechanism, manufacturing process and intended clinical application.
CAR-T Cells
T cells are genetically modified to express a chimeric antigen receptor capable of recognising a selected surface target.
Several autologous CAR-T products are authorised for selected leukaemias, lymphomas and multiple myeloma.
Tumour-Infiltrating Lymphocytes
TIL therapy uses lymphocytes recovered from tumour tissue, expanded to large numbers and administered following preparative treatment.
Product-specific use has been authorised for selected patients with advanced melanoma.
Haematopoietic Cell Transplantation
Haematopoietic stem and progenitor cells restore or replace blood and immune-cell production following conditioning.
Transplantation is established for selected blood cancers, marrow disorders and inherited diseases.
Natural Killer Cells
NK cells are innate lymphocytes capable of recognising and eliminating certain malignant, infected or stressed cells without conventional antigen priming.
Autologous, allogeneic, cord-blood-derived, induced-pluripotent-cell-derived and CAR-NK platforms are under investigation.
Dendritic-Cell Therapies
Monocytes or dendritic-cell precursors may be cultured into antigen-presenting cells and loaded with tumour-associated material, peptides, RNA or other antigens.
These cells are intended to stimulate a targeted T-cell response.
T-Cell-Receptor Therapy
T cells may be engineered to express a defined T-cell receptor capable of recognising an intracellular antigen presented through an appropriate HLA molecule.
Regulatory T Cells
Regulatory T-cell products are developed to reduce excessive immune activation and promote immune tolerance.
Research includes transplantation, autoimmune disease and inflammatory disorders.
Virus-Specific T Cells
T cells may be selected or expanded for recognition of viral antigens, particularly in immunocompromised or transplant patients.
Macrophage and Myeloid Therapies
Macrophages, monocytes and related myeloid cells are being investigated for tumour targeting, antigen presentation, tissue repair and immune regulation.
Laboratory Manufacturing
From patient or donor material to a cellular product
The exact workflow differs substantially among CAR-T, TIL, NK-cell, dendritic-cell and regulatory-cell products.
Patient and Protocol Evaluation
Confirm diagnosis, treatment objective, eligibility, prior therapies, organ function, infectious-disease status and applicable regulatory requirements.
Cellular Collection
Obtain leukocytes through leukapheresis, blood collection, tumour resection, marrow collection or another qualified source.
Cell Selection
Enrich the required population using immunomagnetic selection, flow-based methods, adherence, density separation or other validated procedures.
Activation or Differentiation
T and NK cells may be activated for expansion. Monocytes may be differentiated into dendritic cells using defined cytokines and culture conditions.
Genetic Modification Where Applicable
CAR-T, CAR-NK or TCR products may be modified using viral vectors, non-viral transfer, gene-editing systems or related technologies.
Antigen Loading Where Applicable
Dendritic cells may be loaded with peptides, tumour lysate, RNA, proteins or other defined antigenic material.
Cellular Expansion
Expand the selected cells under controlled media, cytokine, density, vessel and environmental conditions.
Harvest and Formulation
Wash, concentrate, count and formulate the cells for fresh administration or controlled cryopreservation.
Release and Clinical Coordination
Review identity, viability, purity, potency, sterility-related results and chain of identity before clinical release.
Differentiation and Activation
Are immune-cell therapies differentiated in the laboratory?
Some immune-cell products are differentiated, while others are primarily selected, activated, expanded or genetically modified.
Monocytes may be differentiated into dendritic cells. Haematopoietic stem and progenitor cells can generate lymphoid and myeloid immune-cell lineages. Pluripotent-cell platforms are also being studied as sources of NK cells and other immune cells.
Mature T cells used for CAR-T manufacturing are generally activated, genetically modified and expanded rather than differentiated from pluripotent or mesenchymal stem cells.
Related Cellular Technologies
Relationship to stem cells, secretome and extracellular vesicles
These fields intersect scientifically, but they should not be presented as interchangeable therapies.
Haematopoietic Stem Cells
HSCs restore the blood-forming system and generate multiple immune-cell lineages following transplantation or controlled differentiation.
Mesenchymal Stromal Cells
MSCs may influence immune-cell behaviour through cytokines, metabolites, cell contact and extracellular-vesicle-associated signalling.
Immune-Cell Secretome
Activated immune cells release cytokines, chemokines, enzymes, metabolites and other factors that coordinate immune responses.
Immune-Cell Extracellular Vesicles
T cells, NK cells, dendritic cells, macrophages and other immune cells release EVs that participate in intercellular signalling.
Cell-Free Immune Research
Immune-cell-derived EVs and secretome fractions are being studied as biomarkers, delivery systems and potential cell-free immunomodulatory products.
Co-Culture Systems
Immune cells may be studied with tumour cells, MSCs, dendritic cells or organoid systems to evaluate activation, suppression and target-cell killing.
Manufacturing Comparison
How major immune-cell platforms differ
| Platform | Typical Source | Principal Laboratory Processing | Development Model | General Clinical Status |
|---|---|---|---|---|
| CAR-T Cells | Patient or donor T cells | Selection, activation, genetic modification, expansion and formulation | Commonly autologous; allogeneic platforms under development | Authorised products exist for selected haematological malignancies |
| TIL Therapy | Patient tumour tissue | Lymphocyte recovery, selection and extensive expansion | Patient-specific autologous product | Product-specific authorisation exists for selected melanoma patients |
| NK-Cell Therapy | Blood, donor cells, cord blood, HSPCs or pluripotent-cell platforms | Selection, activation, expansion and optional engineering | Autologous or allogeneic | Predominantly investigational |
| Dendritic-Cell Therapy | Patient monocytes or dendritic-cell precursors | Differentiation, maturation and antigen loading | Commonly patient-specific | Limited authorised use and ongoing clinical research |
| Regulatory T Cells | Patient, donor or progenitor-cell source | Selection, expansion and optional antigen-specific engineering | Autologous or allogeneic | Primarily investigational |
| HSC Transplantation | Bone marrow, peripheral blood or cord blood | Collection, selection, cryopreservation and transplantation | Autologous or allogeneic | Established for defined diseases |
Current Medical Use
Established and authorised cellular applications
Authorisation is product-specific, indication-specific and jurisdiction-specific. It should not be interpreted as general approval of an entire immune-cell category.
Haematopoietic Stem-Cell Transplantation
Autologous and allogeneic transplantation is used for selected leukaemias, lymphomas, myeloma, marrow-failure disorders and inherited haematological diseases.
CAR-T Therapy
CAR-T products are authorised for selected B-cell malignancies and multiple myeloma according to the specific target, product label and patient eligibility criteria.
TIL Therapy
Lifileucel is an autologous tumour-infiltrating lymphocyte product authorised in the United States for defined patients with advanced melanoma.
Antigen-Presenting Cell Therapy
Certain autologous antigen-presenting-cell products have authorised uses in narrowly defined oncology settings.
Donor Lymphocyte Infusion
Donor lymphocytes may be administered after allogeneic transplantation to support graft effects against selected haematological malignancies.
Virus-Specific T Cells
Specialised cellular programmes may use virus-specific T cells for selected severe viral infections in immunocompromised or transplant patients.
Potential Uses and Indications
Principal areas of clinical investigation
These categories describe active research fields and do not establish that an immune-cell therapy is safe, effective or authorised for a particular patient.
Solid Tumours
CAR-T, CAR-NK, TCR, TIL, dendritic-cell and macrophage platforms are being investigated for solid tumours.
Autoimmune Disease
CAR-T cells, regulatory T cells and immune-reconstitution approaches are being studied for selected severe autoimmune disorders.
Transplant Tolerance
Regulatory-cell therapies are being evaluated for prevention of rejection and excessive immune responses after organ or cell transplantation.
Infectious Disease
Antigen-specific T-cell and NK-cell platforms are being studied for viral, fungal and other severe infections in high-risk patients.
Neurological Autoimmunity
Immune-resetting and regulatory-cell strategies are being investigated for selected neuroinflammatory and autoimmune conditions.
Inflammatory Disorders
Regulatory immune-cell platforms may have potential applications in severe inflammatory and immune-dysregulation syndromes.
Universal Donor Cells
Gene-edited T-cell and NK-cell platforms are being developed to reduce rejection and enable standardised donor-derived manufacturing.
Pluripotent-Cell-Derived Immune Cells
iPSC-derived NK cells and related immune-cell platforms are being developed as scalable, renewable manufacturing sources.
Immune-Cell-Derived EVs
Extracellular vesicles from NK cells, dendritic cells and other immune cells are being studied as cell-free signalling and delivery platforms.
Product Development Models
Individual manufacturing or scalable cellular product?
Some immune-cell therapies must be produced for one named patient. Others may be developed from qualified donor or stem-cell banks as standardised batches.
Patient-Specific Autologous Manufacturing
Cells are collected from the intended patient, processed under an individual chain of identity and returned to that same patient.
- Patient-specific collection
- Individual chain of identity
- Patient-linked manufacturing record
- Batch-specific release testing
- Treatment-centre coordination
- Long-term clinical follow-up where required
Allogeneic or Bank-Derived Manufacturing
Cells originate from qualified donors, cord blood, HSPCs or pluripotent-cell banks and may support production of multiple treatment units.
- Qualified master-cell source
- Controlled donor eligibility
- Standardised expansion process
- Gene editing where applicable
- Cryopreserved inventory
- Product-specific regulatory authorisation
“Off-the-shelf” does not mean ordinary mass marketing
A bank-derived immune-cell product may be manufactured at scale, but it remains a complex biological medicine requiring product specifications, controlled distribution, clinical eligibility, pharmacovigilance and regulatory oversight.
It should not be marketed as a general wellness, anti-ageing or non-specific immune-boosting procedure.
Characterisation and Quality Control
Living immune-cell products require multiparametric release testing
Testing must address cellular identity, composition, safety, potency, genetic modification and product stability.
Cellular Identity
Confirm the intended T-cell, NK-cell, dendritic-cell, regulatory-cell or progenitor-cell phenotype.
Viability and Cell Dose
Establish viable-cell concentration, total dose, recovery and acceptable viability limits.
Cellular Purity
Measure unwanted lymphocyte, myeloid, progenitor or residual cellular populations.
Sterility-Related Testing
Evaluate microbial contamination, mycoplasma and endotoxin using fit-for-purpose methods.
Potency
Assess target-cell killing, cytokine response, antigen presentation, suppression or another mechanism-relevant biological activity.
Genetic Modification
Evaluate transgene expression, editing outcome, vector-related attributes and unintended genetic changes where applicable.
Replication-Competent Agents
Viral-vector-based processes may require testing and controls for replication-competent viral contaminants.
Cryopreservation and Recovery
Determine whether freezing, storage, transport and thawing affect viability, phenotype or potency.
Chain of Identity and Custody
Maintain documented control from collection through manufacturing, shipment, administration and follow-up.
Clinical Safety
Immune activation may produce serious adverse effects
Cytokine-Release Syndrome
Rapid immune activation may produce fever, hypotension, respiratory compromise and multi-organ effects requiring specialist monitoring and treatment.
Neurological Toxicity
Certain cellular immunotherapies may cause confusion, language disturbance, seizures or other neurological complications.
On-Target Effects
A therapy may also damage healthy cells that express the intended target antigen.
Prolonged Cytopenias and Infection
Conditioning therapy and immune-cell treatment may reduce normal blood-cell populations and increase infection risk.
Graft-Versus-Host Disease
Donor-derived T cells may recognise recipient tissues as foreign unless appropriately selected, controlled or engineered.
Long-Term Surveillance
Genetically modified cell products may require prolonged follow-up for delayed adverse events and persistence.
Clinical and scientific qualification
Immune-cell therapy is a broad category. Evidence for one CAR-T, TIL, NK-cell or dendritic-cell product does not establish safety or effectiveness for another product.
Mature immune cells are not ordinarily produced from mesenchymal stromal cells. T cells, B cells, NK cells and myeloid cells arise principally from haematopoietic stem and progenitor cells.
Laboratory activation, expansion or genetic modification does not independently establish clinical benefit.
Patient-specific manufacture does not remove the need for controlled facilities, product testing, ethical review, clinical eligibility and applicable regulatory authorisation.
Immune-cell therapies should not be represented as non-specific immune boosters, anti-ageing products or universal treatments for cancer, autoimmune disease, infection or neurological disorders.
Administration should occur only through an authorised medical programme with appropriate specialist supervision, emergency capability and follow-up.
The CELLMEX Approach
Product-specific cellular science and responsible clinical translation
Define the Immune-Cell Platform
Distinguish T-cell, NK-cell, dendritic-cell, regulatory-cell, myeloid-cell and progenitor-cell programmes.
Establish Source and Traceability
Document patient or donor identity, collection, transport, eligibility and chain of custody.
Control Cellular Manipulation
Define selection, activation, differentiation, genetic modification, expansion and formulation.
Characterise the Final Product
Evaluate identity, purity, viability, potency, microbiological safety and genetic attributes.
Coordinate Clinical Administration
Connect manufacturing release with patient eligibility, conditioning, administration, toxicity management and follow-up.
Match Claims to Evidence
Separate authorised medical use from early clinical development, laboratory research and theoretical applications.
Selected Scientific and Regulatory References
Immune-cell biology, manufacturing and clinical use
U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products.
Current FDA listing of authorised cellular and gene therapy products, including CAR-T and tumour-infiltrating-lymphocyte products.
View FDA product listU.S. Food and Drug Administration. Considerations for the Development of Chimeric Antigen Receptor T-Cell Products.
FDA guidance concerning CAR-T product design, manufacturing, nonclinical and clinical development.
View FDA guidanceEuropean Medicines Agency. Advanced Therapy Medicinal Products: Overview.
European regulatory framework for gene therapies, somatic-cell therapies and tissue-engineered medicinal products.
View EMA informationNational Cancer Institute. Adoptive Cell Therapy.
NCI terminology and information concerning CAR-T, tumour-infiltrating lymphocyte and related cellular immunotherapies.
View NCI informationNational Cancer Institute. Therapeutic Autologous Dendritic-Cell Clinical Trials.
Clinical-trial information concerning personalised dendritic-cell therapeutic development.
View NCI trialsNational Cancer Institute. Personalised Dendritic-Cell Vaccine Technology.
Description of monocyte collection, differentiation into dendritic cells, antigen loading and maturation.
View NCI technology informationMa S, et al. Natural Killer Cell-Based Immunotherapy for Cancer.
Review of autologous, allogeneic, unmodified and genetically engineered NK-cell platforms.
View publicationEuropean Medicines Agency. Guideline on Quality, Nonclinical and Clinical Requirements for Investigational Advanced Therapy Medicinal Products.
Development and clinical-trial considerations for advanced cellular and gene-therapy products.
View EMA guideline
Scientific Information
Request information concerning CELLMEX immune-cell research
Physicians, researchers and institutions may request information concerning immune-cell biology, cell-selection systems, dendritic-cell development, immune-cell secretome research, analytical methods and potential scientific collaboration.